Showing results (221-230 of 240) with videos related to

Sort By:
Pageof 24
Acta Anaesthesiologica Scandinavica|March 14, 2025
INCEPT: The Intensive Care Platform Trial-Design and protocolAnders Granholm, Morten Hylander Møller, Benjamin Skov Kaas-Hansen, et al.
JAMA|September 3, 2020
Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis, Jonathan A C Sterne, Srinivas Murthy, et al.
Acta Anaesthesiologica Scandinavica|February 14, 2021
Higher vs lower doses of dexamethasone in patients with COVID-19 and severe hypoxia (COVID STEROID 2) trial: Protocol and statistical analysis planM W Munch, Anders Granholm, S N Myatra, et al.
Journal of Clinical Epidemiology|February 9, 2021
A new tool to assess Clinical Diversity In Meta-analyses (CDIM) of interventionsMarija Barbateskovic, Thijs M Koster, Ruben J Eck, et al.
Critical Care Medicine|January 6, 2025
A Core Outcome Set for Adult General ICU PatientsMaj-Brit Nørregaard Kjær, Camilla Rahbek Lysholm Bruun, Anders Granholm, et al.
Acta Anaesthesiologica Scandinavica|August 12, 2020
Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia (COVID STEROID) trial-Protocol and statistical analysis planMarie Warrer Petersen, Tine Sylvest Meyhoff, Marie Helleberg, et al.
Critical Care Medicine|March 4, 2025
A Core Outcome Set for Adult General ICU PatientsMaj-Brit Nørregaard Kjær, Camilla Rahbek Lysholm Bruun, Anders Granholm, et al.
Acta Anaesthesiologica Scandinavica|February 14, 2021
Higher vs Lower Doses of Dexamethasone in Patients with COVID-19 and Severe Hypoxia (COVID STEROID 2) trial: Protocol for a secondary Bayesian analysisAnders Granholm, Marie Warrer Munch, Sheila Nainan Myatra, et al.
Intensive Care Medicine|November 10, 2021
Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trialAnders Granholm, Marie Warrer Munch, Sheila Nainan Myatra, et al.
Intensive Care Medicine|April 1, 2022
Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemiaAnders Granholm, Maj-Brit Nørregaard Kjær, Marie Warrer Munch, et al.
Pageof 24